Introduction

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), known as a cluster of differentiation CD152, is a key human immune checkpoint molecule. CTLA-4 is a member of the immunoglobulin superfamily that acts as a co-inhibitory receptor and shares the same ligands, B7s, with the co-stimulatory receptor, CD28. After T cell activation, CTLA-4 receptors predominantly express on activated T lymphocytes, competitively bind to b7-ligands, and induce inhibitory signals through both cell-extrinsic and intrinsic mechanisms (1, 2). This interaction eventually leads to a decrease in T cell proliferation and differentiation, cell cycle progression, and cytokine production. Consequently, CTLA-4 down-regulates immune responses and brings immune homeostasis (3, 4).

Significantly, over-expression of checkpoint inhibitory molecules, such as CTLA-4, was presented as a strategy of cancer cells to evade the immune system. This may indicate the important role of CTLA-4 action in regulating anti-tumor responses (5, 6). Different studies revealed the existence of an association between CTLA-4 gene polymorphisms and numerous cancers, for instance; melanoma, breast cancer, non-small cell lung cancer (NSCLC), skin cancer, gastric cancer, colorectal cancer, and many others (7). Although the CTLA-4 expression profile does not stay steady along with cancer progression, the over-expression of CTLA-4 seems to be a noticeable cancer-biomarker (8, 9). In this regard, clinical achievements in cancer therapy with checkpoint inhibitors (CPI) revealed blocking inhibitory immune checkpoint molecules such as CTLA-4 and human programmed cell death protein 1 (PD1) resulted in significant therapeutic approaches (10). Noticeably, anti-CTLA-4 molecules enable the anti-tumor activity of T cells and reduce inhibitory signals through different mechanisms (11). FDA has approved several monoclonal antibodies (mAbs) as CPIs for different cancer types (12). Heavy-chain Antibodies (HcAbs) are another group of immunoglobulins with a molecular weight of

Result:

The most abundant gene was identified as VHH-49 and screened by phage display technique. Specific nanobodies against CTLA-4 protein were selected with longer CDR3 and a higher binding rate, were selected for more assays.

Conclusion:

Taken together, this developed camelid-specific anti-CTLA-4 Nanobody 3hCTL55, selected from a high-quality immune library by phage display technique, may be effective for further study about cancer diagnosis and cancer-therapy purposes.
~90 kDa. HcAbs only consist of two heavy chains and have no CH1 domain (13). The antigen recognition site of HcAbs is composed of a single variable domain, called VH or Nanobody (Nb). Due to the distinct advantages of nanobodies, in comparison with conventional mAbs, they are proposed to be more potential diagnostic and therapeutic agents for cancer immunotherapy (14). Nbs are very small, (2.5×4 nm/~15 kDa), which enables them to achieve greater microenvironment penetration (15). These molecules, with an almost conserved sequence, have a "Lego-like" structure and are easily manipulated to combine other molecules for different purposes (16). In comparison with Abs, Nbs are more soluble and more stable in harsh conditions such as extreme temperature and pH. Because of having high-order homology with the human VH domain, Nbs are less immunogenic for humans. Adding to all mentioned beneficial properties, low costing production is another reason that all together encourage scientists to focus on developing Nbs for a variety of research (15).

This study aimed to construct a novel camelid immune library against human recombinant CTLA-4 antigen and produce the strongest and the most specific anti-CTLA-4 Nanobody which was followed by Nanobody characterization with different techniques (17-19).

**Materials and Methods**

**Camel immunization and lymphocyte separation**

Nine-month-old female *Camelus dromedarius* was immunized with 100 µg of recombinant human extracellular domain of CTLA-4 protein (17), mixed with an equal volume of Freund’s complete adjuvant for the first time, and Freund’s incomplete for subsequent injections. After six subcutaneous injections with one-week intervals, an upward trend of the immune response was approved by the serum-ELISA test (17). Whole blood samples were collected as a Nanobody-gene pool, from the immunized camel. Blood was diluted with an equal volume of phosphate-buffered saline (PBS) and then Peripheral Blood Mononuclear Cells (PMBCs) were isolated by density gradient centrifugation at 400 × g for 30 min with Ficoll solution. Isolated PMBC was divided into 5×10⁷ aliquots by using freeze medium culture (90% fetal bovine serum and 10% dimethyl sulfoxide), and then stored at -70 °C for the next step.

**VHH cloning and library construction**

Total RNA was obtained from 5×10⁷ PMBC with RNeasy Mini Kit (Qiagen, Germany), and 40 µg of RNA was used for cDNA synthesizing. Following that, we carried out Nested PCR to amplify VH gene fragments. Briefly, cDNA was undergone the first run of PCR with the first set of primers; CALL001 (leader sequence-specific primer) GTC CTG GCT GCT TCT CTA CAA GG, and CALL002 (CH2-specific primer) GGT ACG TGC TGT TGA GAT ACT GTT CC. Next, 700 bp amplicons were purified from 2% agarose gel and used as a template for the nested primers; VHH-A6E (Framework 1-specific primer) GAT GTG CAG CTG CAG GAG TCT GGR GGA GG) and VHH-38 (Framework 4-specific primer) GGA CTA GTG CCG CCG CTG GAG ACG GTG ACC TGG GT, introducing *PstI* and *NotI* restriction site sequences, respectively. Moreover, the first PCR was set up with annealing temperature at 47.8 °C for 30 sec and 3 amplification cycles which changed to 55 °C for 30 sec and 20 amplification cycles for the second PCR. The second PCR fragments were then cleaned and digested with *PstI* and *NotI* enzymes for 16 hr at 37 °C. Next, the digested fragment was ligated into the pHEN4 vector, containing Hemagglutinin (HA)-tag at C-terminal, with incubation overnight at 16 °C. The purified ligated mixture was transformed into electrocompetent *Escherichia coli* TG1 cells and after one-hour incubation at 37 °C, cells were cultured on Luria-Bertani (LB) agar plates, containing 100 µl ml-1 ampicillin and 2% (wt/vol) glucose. To calculate the electroproportion efficiency and library size, 100 µl of four tenfold serial dilutions were plated on separate LB agar plates. In addition, we carried out colony-PCR for some random colonies with GII (CCA CAG ACA GCC CTC ATA G) and RP (TCA CAC AGG AAA CAG CTA TGA C) primers to measure the insertion rate.

**CTLA-4 specific phage selection**

The bacterial library was converted to the phage VHH library by applying the helper phage VCSM13 (Stratagene, La Jolla, CA, USA). Then, precipitated phages were used for 3 successive bio-panning rounds. Flat-bottom 96-well immunoplates (Nunc maxisorp, Roskilde, Denmark) were coated with 5 µg hCTLA4 in 100 µl carbonate-bicarbonate buffer (pH 9.2) and immobilized at 4 °C, overnight. The negative control well was incubated with 100 µl carbonate-bicarbonate buffer. Wells were blocked by 4% skim milk for one hour at Room temperature (RT). After twice washings with PBS, 100 µl of the phage library (10¹¹ particles) were added to wells and incubated for one hour at RT. To eliminate non-bounded phage particles, wells were washed with PBS-0.05% Tween-20 (PBST) 10 times, which increased to 20 x and 25 x for second and third panning rounds, respectively. High selective bound phages were eluted with triethylamine solution (100 mM, pH 10.0) for 10 min and then immediately was neutralized with Tris-HCl (1 M, pH 8.0). To amplify phages for the next round of selection, *E. coli* TG1 cells were infected by eluted phages, followed by adding 10¹¹ particles of VCSM13 helper phages, for phage rescuing. After three rounds, polyclonal phage ELISA was performed on the hCTLA-4 antigen, to evaluate the enrichment rate of specific phages (18). We picked sixty-four random single colonies to screen with the periplasmic extract ELISA (PE-ELISA) method. Briefly, colonies were cultured and protein expression was induced with 1M IPTG (overnight (O/N) at 28 °C). Then periplasmic proteins were extracted through sucrrose osmotic shock and used for the PE-ELISA (19). A plasmid of positive single colonies was extracted with a plasmid extraction kit (Vivantis, Malaysia) and screened by DNA sequencing (Gene Fanavaran Co.). Further, sequencing results were analyzed in National Center for Biotechnology Information-Basic Local Alignment Search Tool (NCBI-BLAST).

**Large scale expression of VHH and purification**

For protein expression, we selected one colony entitled Nb 3hCTL55 for more characterization. An encoding 55 Nb construct was amplified by PCR and digested with...
PstI and BstEII and subcloned in the pHEN6-C vector. The new recombinant vector was introduced into competent E. coli WK6 with the heat-shock method. Subsequently, a transformed single colony was cultured in 1L LB broth (100 μg ml⁻¹ ampicillin) and induced by 1 mM Isopropyl β- d-1-thiogalactopyranoside (IPTG) (28 °C, 18 hr). Cells were pelleted by centrifuge (3000 x g for 15 min), followed by obliterating osmotic shock to achieve periplasmic extract containing the VHH-His tag. Nb 3hCTL55 purification was done by His-select NiNTA affinity resin (Thermo Fisher Scientific, USA) and then was eluted with PBS-0.5 M imidazole. Elution was concentrated on an Amicon Ultra-2 ml Centrifugal Filter (Merck Millipore, Darmstadt, Germany) with a molecular mass cutoff of 10 kDa. For more confirmation, protein concentration was determined at OD 280 nm and the quality of purification was evaluated by 15% SDS-PAGE and western blotting. Briefly, after SDS-PAGE, bands were transferred from gel to nitrocellulose membrane. Anti-camel antibodies were used to detect Nb. Visualizing was done by 3,3′-diaminobenzidine (DAB).

Nanobody characterization
Antigen binding specificity
We estimated antigen-binding specificity of Nb 3hCTL55 on numerous proteins; human PD1 (Genscript Biotech, USA), recombinant mouse PD1, human programmed death-ligand 1 (hPDL1), (Genscript Biotech, USA), recombinant mouse PDL1, human CTLA-4 (Genscript Biotech, USA), recombinant mouse CTLA-4, casein (Sigma-Aldrich, USA), and bovine serum albumin (Sigma-Aldrich, USA). All washing steps were done three times with 500 μl PBS 1x. ELISA plate was coated with 1 μg/ml of proteins. After blocking with 4% skim milk, wells were washed and incubated with 100 μl of the anti-hCTLA-4 Nb (1 μg/ml) for 2 hr at 37 °C. Then, with washing intervals, 100 μl of the anti-HA tag antibody (1/2000), followed by 100 μl of anti-mouse Horse Radish Peroxidase anti-mouse Horse Radish Peroxidase (HRP) conjugate antibody (1/2000) were added to wells for 1 hr at RT, respectively. After the final washing steps, positive wells were screened by adding 100 μl of 3,3′,5,5′-tetramethylbenzidine (TMB) (Sigma, Germany) solution. The enzymatic reaction was stopped by 2N sulfuric acid and results were considered by measuring the absorbance at 450 nm.

Affinity
The affinity of Nb 3hCTL55 against the CTLA-4 antigen was determined by the Beatty ELISA technique (20). Briefly, the CTLA-4 antigen was diluted with carbonate–bicarbonate buffer (pH 9.2) in two different concentrations (10 & 1 μg/ml) and coated in a 96-well plate at 4 °C overnight. Bovine-Serum-Albumin (BSA) with the same concentration was used as a negative control. All were set up in triplicate. After blocking with 4% skimmed milk, an increasing series (0-100 nM) of Nb 3hCTL55 concentration was added to each well. Then, the ELISA protocol was carried out as described before. Finally, absorbance at 450 nm was measured and the K_{on} value was calculated based on the modified Beatty method (21).

Western blotting on cell lysate
Reactivity of Nb 3hCTL55 with CTLA-4 antigen was assessed with the western blot method. We used commercial human CTLA-4 protein (CTLA-4 Fc Chimera, Human, Genscript, USA) and CTLA-4 protein from cell lysate for this examination. Briefly, Jurkat cells (CTLA-4 positive cell line) and HEK-293 (CTLA-4 negative cell lines) were cultured in RPMI-10%FBS and DMEM-10%FBS medium, respectively. Both cell lines were obtained from the National Cell Bank of Pasteur Institute of Iran. Next, 1x10⁶ cells were harvested and washed twice with PBS and then re-suspended in a non-reduced lysis buffer. Cell lysate and commercial human CTLA-4 protein were exposed on 15% SDS-PAGE gel and proteins were blotted on nitrocellulose paper. After overnight blocking with 4% skim milk, the membrane was incubated (for one hour at RT) with Nb 3hCTL55, Rabbit anti-His (1/2000), and anti-Rabbit HRP-conjugate, respectively. Interval washings were applied three times with PBST. Finally, bands were visualized with DAB.

Flow cytometry
We evaluated the binding potency of the selected Nb 3hCTL55 to the native CTLA-4 receptor expressed on the cell surface of the Jurkat cell line by flowcytometry. Briefly, Jurkat cells (CTLA-4 presenting cells) were washed 2 times with cold PBS-2% FBS and aliquot up to 1x10⁶ cells per ml. Next, cells were incubated with 2 μg of purified Nb 3hCTL55 for 1 hr on ice and then with 1 μg of mouse anti-His for 1 hr. To monitor the conjugated molecules, we used 1 μg of anti-mouse Phycerythrin (PE) conjugate. Finally, cells were washed and fluorescent intensity was measured by using the FL1 channel of the flowcytometer (Cflow, Partec, Germany). Commercial anti-hCTLA-4 (BioLegend, USA), was used for positive and negative control, respectively. Data analysis was done via FlowJo software v. 7.6 (Tree Star, USA).

Statistical analysis
All experiments were repeated twice, in triplicate wells. In statistical analysis, values of P<0.05 were considered significant, which were shown by using a two-tailed unpaired t-test. Regression performing and curve fittings were done with GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA).

Results

Immunization and nanobody library construction
Applying six scheduled injections resulted in boosting the humoral immune response against recombinant human CTLA-4 protein, as reported previously (17). The ELISA was done with a diluted immunized camel sera sample. Total IgG titers marked up to 1/14000 and showed an upward trend of camel immunization after each boost injection (Figure 1).

To construct the library, the RNA of PMBC was used as a template in PCR. Consequently, the first PCR generated two distinct PCR amplicons with 900 bp (VH), and also 700 bp (originates from HcAb-encoding mRNA/VHH)(Figure 2A). The second PCR amplified only VHH sequences with 400 bp (Figure 2B). Following transformation, appeared colonies were counted from the gradient diluted plates and revealed that the library
had approximately $10^8$ independent transformed bacteria. Transformation efficiency was estimated at 90% with the colony PCR method (Figure 3). Colonies were collected, mixed with 1% glycerol, and stored at -70°C.

**Panning and nanobody selection**

Polyclonal phage ELISA showed that phage enrichment against hCTLA-4 tended to increase over three consecutive bio-panning rounds (Figure 4). Screening of 64 colonies was done with the PE-ELISA technique to find the specific and strong Nbs against the hCTLA-4 antigen. Comparing positive and negative wells, 29 colonies with at least two-fold absorbance at 450 nm were chosen as positive colonies for further investigation (Figure 5). Results of the sequencing revealed the existence of two main diversities in the library (Figure 6A). Clone No. 55, expressing Nanobody with a longer CDR3 fragment (Figure 6B), was selected for further evaluation.

**VHH expression and purification**

To characterize the selected Nanobody, Nb 3hCTL55, we sub-cloned the VHH gene into the pHEN6C vector and transformed it into an E. coli WK6 host. IPTG induction resulted in producing Nb in periplasmic space which was released by osmotic shock. Purification and concentration of Nb yielded a sharp band with approximately 17 kDa molecular weight on 15% SDS-PAGE gel (Figure 7A) and nitrocellulose membrane (Figure 7B).

**Assay**

**Antigen specificity**

The antigen specificity of Nanobody 3hCTL55 was assessed against eight different proteins with the ELISA technique. Colorimetric readings were done at a wavelength of 450 nm ($OD_{450}$). Results showed Nb 3hCTL55 was not able to detect seven other proteins except hCTLA-4. Nb 3hCTL55 specifically bound hCTLA4.
protein and had the maximum absorption of 2.3 which was less than 0.5 for other antigens (Figure 8).

**Affinity**

The affinity of 3hCTL55 Nb binding to hCTLA-4 antigen was calculated by using modified equation of Beatty; $k_{\text{aff}} = \frac{n - 1}{2(n[Nb] - [Nb'])}$, where $n$ is $\frac{[Ag]}{[Ag']}$, $[Ag]$; the concentration of 10 µg/mL antigen, $[Ag']$; the concentration of 1 µg/ml antigen and $[Nb]$ and $[Nb']$ are the concentrations of Nanobody at %50 OD 450 (Max) in the Ag and Ag' curves. Following the equation, $K_{\text{aff}}$ was calculated as $50 \times 10^{-9}$ M. GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA), (Figure 9)(21).

**Western blotting on whole cell lysate**

We estimated the binding ability of Nb 3hCTL55 to commercial human CTLA-4 protein and also CTLA-4 receptors of the whole-cell lysate of Jurkat cells with the western blot technique. Protein-protein interactions were detected by color development with DAB. As a result, Nbs were able to bind commercial hCTLA-4 protein with a molecular weight of 48 kDa (Figure 10A). Applying Nb 3hCTL55 to the cell lysate in western blotting also showed Nb 3hCTL55 were able to recognize CTLA-4 protein conformation in cell lysate and bind it (Figure 10B). A band with about 50 kDa molecular weight on the nitrocellulose membrane relates to the dimerization of CTLA-4 protein visualized in SDS-PAGE gel.
Flowcytometry

To evaluate the specific interaction of Nb 3hCTL55 with CTLA-4 presented on the cell, we performed Flowcytometry. Results confirmed that Nb 3hCTL55 were able to specifically bind to CTLA-4 receptors on Jurkat cells and had no cross-reaction with negative cells, HEK293 (Figure 11).

Discussion

Cancer therapy with immune checkpoint inhibitors is a progressive treatment strategy for many cancers. This method relies on blocking immune inhibitory molecules and modulating anti-tumor immune responses (22). CTLA-4, PD1, and its ligand (PDL1) are the principal human inhibitory immune checkpoints that have been overexpressed in a broad range of cancers and are the main target molecules for CPI cancer therapy (23, 24). In 2011, FDA approved the first anti-CTLA-4 monoclonal antibody, (called Ipilimumab (YERVOY®, IgG1)) for advanced melanoma (25). Afterward, because of the positive clinical achievements, several monoclonal antibodies were added to a list of FDA CPI cancer therapy agents. Nivolumab and pembrolizumab (anti-PD-1), atezolizumab,avelumab, and durvalumab (anti-PD-L1) antibodies are some examples. Some other mAbs such as Tremelimumab (anti-CTLA-4, IgG2) are progressing in preclinical and clinical trials to use single or combine with other agents for different types of cancers (12). During the past decades, a great number of small therapeutic proteins with the conventional monoclonal-antibody-derived regions including Fab, Fc-fusion protein, and scFv, have been developed. Despite many advantages and significant clinical and research applications of classical antibodies, they have some restrictions (26, 27). They are big (150kDa) and also require having both heavy and light variable domains (VH & VL) to bind to antigens. In line with this fact, developing new anti-CTLA-4 molecules with more specific diagnostic and therapeutic potential and fewer limitations are a concern of many pieces of research (28, 29).

Recently, reports show interest in using the smallest antibody fragment of heavy chain antibodies, called VHH or Nanobody, is growing (15, 30). Various renowned biopharmaceutical companies have been concentrating their efforts on these small molecules (31). Significantly, the number of Nanobody drugs entering clinical-trial studies is increasing (29). These nano-antibodies are multi-potent “Lego-like” molecules that can be designed for different purposes. Many Nb-associated agents were developed by manipulating Nb fragments to bind to Nb/Nbs (bivalent/multivalent Nb agent), florescent dye, peptide or protein, radionuclide, drug or toxin, enzyme, nanoparticle, and others (16).

In the current study, we developed a monoclonal single variable domain antibody against human CTLA-4 antigen. This was followed by gene expression and protein characterization of the selected Nb. There are four well-known human antibody sources; immune library, naïve library, semi-synthetic, and synthetic library. All libraries have several advantages and disadvantages.

**Figure 9.** Affinity graph. The affinity of 3hCTL55 Nb binding to hCTLA-4 antigen was calculated by using modified Beatty’s equation

**Figure 10.** Evaluating the binding ability of Nb 3hCTL55 to CTLA-4 antigen with western blot (A) Applying Nb 3hCTL55 to commercial human CTLA-4 protein. 1; Nanobody-commercial hCTLA-4 antigen interaction M; protein marker, (B) Applying Nb 3hCTL55 to Jurkat and HEK-293 cell lysate as a positive and negative cell, respectively. 1; Jurkat cell lysate and Nb 3hCTL55 2; HEK-293 cell lysate and Nb 3hCTL55 M; Protein marker

**Figure 11.** Flowcytometry. Specific interaction between Nb 3hCTL55 and CTLA-4 receptors on cells was evaluated with the Flow-cytometry technique by using the FL1 channel (X-axis). Nb 3hCTL55 was able to specifically bind to the native form of CTLA-4 receptors on Jurkat cells (presenting cell line) and make no interaction with HEK-293 cells. MFI: Median Fluorescence Intensity
Specific nanobody against human CTLA-4

Low-cost and short-time processing, the possibility to use different forms of antigens, natural antibody maturation, and producing high-affinity antibodies are some advantages of immune libraries (32). In addition, using pure recombinant protein antigens to stimulate the immune system will result in more specific antibody maturation, comparing with using other kinds of antigens such as cell lysate, whole proteins, or pathogen (e.g., toxin) and a mixture of cell lysate and protein (32). Indeed, to achieve a wide variety of benefits in a small library, we boosted a C. dromedarius immune system against in-house made recombinant human CTLA-4 protein (hCTLA-4), as previously explained (17). Then, an immune library of VHH-cDNA with a diversity of anti-CTLA-4 nano-antibody repertoires was constructed by using camel PBMC which resulted in 10^6 binders.

There are two main display techniques; cell-based display and cell-free display. Phage display is a cell-based technique that brings great benefits as the most common and standard selection technique (33). Therefore, CTLA-4 specific nanobodies from the VHH library, displayed on VCM13 phages, were enriched by three sequential bio-panning rounds (R1, R2, and R3) against commercial CTLA-4 antigen. Performing the phage-ELISA method showed a gradual threefold increase of enrichment factor from Round 1 to Round 3 and confirmed library enrichment. We applied PE-ELISA for monoclonal screening which was followed by nucleotide sequencing of selected colonies. Results revealed the existence of diversity in two clones in the library.

Structurally, Nanobody consists of four conserved framework regions (FW1/2/3/4) and three hypervariable antigen-binding loops, called complementarity determining regions (CDR1/2/3). The CDR3 loop of nanobodies has a finger-like structure with a mean of 18 amino acid residues that enable nanobodies to bind antigens. The longer the CDR3 sequence, the better interaction with antigen (29). For this reason, we chose one Nanobody of the cluster with a longer CDR3, with 19 amino acid residues (Figure 6) named 3hCTL55. Followed by the large-scale expression of Nb 3hCTL55, more characterization was done after periplasmic extraction and Ni-affinity chromatography purification and concentration.

The specificity of Nb 3hCTL55 to hCTLA4 antigen was assessed by the ELISA technique. Compared with seven other antigens, Nb 3hCTL55 specifically detected immobilized commercial hCTLA-4 protein and had no cross-reaction with other proteins. Additionally, we confirmed the specific binding of Nb 3hCTL55 to both commercial CTLA-4 antigens and CTLA-4 receptors from CTLA-4 expressing cell lysates with western blotting.

The ability to recognize the native form of an antigen is a particular feature of an antibody to make the antibody-antigen interaction. This feature exposes the specificity and affinity of an antibody to an antigen (34, 35). Using the Flowcytometry technique by Wen et al. revealed the developed anti-peptide PD1125-126 Nanobody was able to bind PD1 antigen and block the binding site of the PD1/PDL1 interaction interface (36). We applied Flowcytometry which showed Nb 3hCTL55 were able to detect CTLA-4 antigens on the surface of the CTLA-4 expressing cells. We compared flow cytometry peaks relating to the interaction of anti-CTLA4 polyclonal antibody and Nb 3hCTL55 with native CTLA-4 antigens on the cell surface. Results explained Nb 3hCTL55 was able to properly detect native CTLA-4 antigens and bind them. By using the modified Beatty method, we calculated the Nb 3hCTL55 affinity to CTLA-4 antigen as 50×10^9 M. Banihashemi et al. showed using a cocktail of two developed nanobodies was able to shift the Flow cytometry binding peak to the right side. This can be the result of the synergy effects of using two nanobodies (37).

Blocking human immune checkpoint by using Nbs is now under investigation. In 2018, Wan et al. examined the effectiveness of in-house produced recombinant anti-CTLA-4 Nb16 molecules on melanoma-bearing mice. Results showed Nb16 delayed tumor growth and increased survival time (38).

Later in 2019, Wen et al. used a humanized Nanobody phage display library to screen and select a specific Nanobody against PD1 molecules. They showed selected PD1-Nb-B20 nanobodies potentially bound to the PD1 molecules and blocked the interaction interface of PD1/PDL1 on the surface of over-expressing PDL1 cells (36). Recently, in 2020, researchers constructed a cameld immune library against PDL1 molecules, showed three anti-PDL1 nanobodies specifically bound to PDL1 molecules confirmed to have a high affinity to PDL1 (39).

In this article, we represented a novel and unique anti-CTLA-4 Nanobody (3hCTL55) with a particular sequence and specifications that were totally different from what was presented in the Wan et al. article. We examined the specificity of our Nanobody which was unique and showed a noticeable affinity for detecting and binding to CTLA-4 proteins on the surface of the cells.

Conclusion

We developed a novel anti-CTLA-4 Nanobody, 3hCTL55, selected from a high-quality immune library by phage display technique that was capable of specifically binding to CTLA-4 antigen in native form. It can be effective for further study of cancer diagnosis and cancer therapy purposes.

Acknowledgment

This study was financially supported by National Institute for Medical Research Development (NIMAD) (grant number 943314) and Pasteur Institute of Iran (grant number 994). The results presented in this paper were part of a student thesis. The authors wish to express their deepest gratitude to Aida Hasanazadeh Eskafi, Reyhaneh Roshan, Shamsi Naderi for their technical support.

Authors’ Contributions

NS, MB Study conception or design; ZN, FK Data analyzing and draft manuscript preparation; MB, MH Critical revision of the paper; NS, MB Supervision of the research; MB Data Processing, Collection, Perform Experiment.

Conflicts of Interest

No competing financial interests exist.
Improved survival with ipilimumab in naturally occurring cancers: a systematic review and meta-analysis. Sci Rep 2017; 7:11493.

2. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852-863.

3. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: A moving target in immunotherapy. Blood 2018; 131:58-67.

4. Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: From mechanism to autoimmune therapy. Int Immunopharmacol 2020; 80:106221.

5. Mocellin S, Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta Rev Cancer 2013; 1836:187-196.

6. Tsai H-F, Hsu P-N. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. J biomed Sci 2017; 24:1-8.

7. Zhao Y, Yang W, Huang Y, Cui R, Li X, Li B. Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem 2018; 47:721-734.

8. Yu H, Yang J, jiao S, Li Y, Zhang W, Wang J. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol Immunother 2015; 64:853-860.

9. Hu P, Liu Q, Deng G, Zhang J, Liang N, Xie J, et al. The prognostic value of cytotoxic T-Lymphocyte antigen 4 in cancers: a systematic review and meta-analysis. Sci Rep 2017; 7:42913.

10. Wieder T, Eigentler T, Brenner E, Rücken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol 2018; 142:1403-1414.

11. Liu Y, Zheng P. How does an anti-CTLA-4 antibody promote cancer immunity? Trends Immunol 2018; 39:953-956.

12. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018; 8:1069-1086.

13. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446-448.

14. Van Audenhove I, Gettemans J. Nanobodies and the promise of modular therapeutics: big opportunities for small antibodies. Drug Discov Today 2016; 21:1076-1113.

15. Muyldermans S. Nanobodies: natural single-domain antibodies devoid of light chains. Nature 1987; 328:267-270.

16. HS, Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc 2014; 9:674-693.

17. Sotoudeh N, Noormohammadi Z, Habibi-Anbouhi M, Kazemi-Lomedasht F, Behdani M. Evaluation of Laboratory Application of Camelid Sera Containing Heavy-Chain Polyclonal Antibody Against Recombinant Cytotoxic T-Lymphocyte-Associated Protein-4. Monoclon Anti Immunodiagn Immunother 2019; 38:235-241.

18. Lee CM, Jorno N, Sierra F, Christ D. Selection of human antibody fragments by phage display. NatProtoc 2007; 2:3001.

19. Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc 2014; 9:674-693.

20. Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 1987; 100:173-179.

21. Roshan R, Naderi S, Behdani M, Cohan RA, Ghaderi H, Shokrgozar MA, et al. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy. Mol Immunol 2021; 129:70-77.

22. Darwin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018; 50:1-11.

23. Brunet J-F, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M, Mattei M-G, et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987; 328:267-270.

24. Rothschilds AM, Wittrup KD. What, why, where, and when: bringing timing to immuno-oncology. Trends Immunol 2019; 40:12-21.

25. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.

26. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220-233.

27. Samaranayake H, Wirth T, Schenkevin D, Rätty JK, Yllertuuala S. Challenges in monoclonal antibody-based therapies. Ann Med 2009; 41:322-331.

28. Jabir NR, Anwar F, Firoz CK, Oves M, Kamal MA, Tabrez S. An overview on the current status of cancer nanomedicines. Curr Med Res Opin 2018; 34:911-921.

29. Jóvčeska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs 2020; 34:11-26.

30. Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol 2017; 8:1442.

31. Steeland S, Vandenbergroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today 2016; 21:1076-1113.

32. Liu W, Song H, Chen Q, Yu J, Xian M, Nian R, et al. Recent advances in the selection and identification of antigen-specific nanobodies. Mol Immunol 2018; 96:37-47.

33. Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. Mabs 2016; 8:1177-1194.

34. Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol 2017; 8:1603.

35. Farajpour Z, Rahbarizadeh F, Kazemi B, Ahmadvand D. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment. Biochem Biophys Res Commun 2014; 446:132-136.

36. Wen B, Zhao L, Wang Y, Qiu C, Xu Z, Huang K, et al. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1). Prep Biochem Biotech 2020; 50:252-259.

37. Banhashemi SR, Hosseini AZ, Rahbarizadeh F, Ahmadvand D. Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes. Iran J Basic Med Sci 2018; 21:455.

38. Wan R, Liu A, Hou X, Lai Z, Li J, Yang N, et al. Screening and antitumor effect of an anti-CTLA-4 nanobody. Oncol Rep 2018; 39:511-518.

39. Li S, Jiangu K, Wang T, Zhang W, Shi M, Chen B, et al. Nanobody against PDL1. Biotechnol Lett 2020:1-10.